Table 1.
Baseline characteristics of enrolled patients (N=102)
| Number/mean ± S.D. | |
|---|---|
| Age | 46.4 ± 11.2 |
| Women/men (N, %) | 35/67 (34/66) |
| Total bilirubin (mg/dL) | 1.2 ± 1.0 |
| AST (U/L) | 196.6 ± 532.2 |
| ALT (U/L) | 224.9 ± 440.8 |
| Albumin (g/dL) | 4.0 ± 0.4 |
| Platelet count (x103/mm3) | 165.1 ± 57.3 |
| Prothrombin time (INR) | 1.1 ± 0.2 |
| Ascites (N, %) | 8 (8) |
| Hepatic encephalopathy (N, %) | 0 (0) |
| HBeAg positivity (N, %) | 71 (70) |
| HBV DNA level (IU/mL, median with interquartile range) | 7340040.5 (474098.3 - 138000000) |
| Liver cirrhosis (N, %) | 36 (35) |
| Child-Pugh class A/B/C (N, %) | 94/6/2 (92/6/2) |
| APRI | 4.5 ± 8.2 |
| FIB-4 | 2.9 ± 4.3 |
| Total cholesterol (mg/dL) | 176.6 ± 32.2 |
| Triglyceride (mg/dL) | 101.5 ± 52.4 |
| HDL cholesterol (mg/dL) | 56.0 ± 15.9 |
| LDL cholesterol (mg/dL) | 104.8 ± 27.2 |
| Fasting blood glucose (mg/dL) | 96.2 ± 19.1 |
| Systolic blood pressure (mg/dL) | 122.1 ± 14.8 |
| Diastolic blood pressure (mg/dL) | 76.9 ± 10.7 |
| Significant alcohol consumption* (N, %) | 19 (19) |
| Diabetes mellitus (N, %) | 4 (4) |
| Hypertension (N, %) | 5 (5) |
| Body mass index (kg/m2) | 23.6 ± 3.1 |
| Waist circumference† (cm) | 82.5 ± 9.4 |
| Waist-to-hip ratio† | 0.86 ± 0.08 |
| Visceral fat area† (cm2) | 89.1 ± 40.8 |
| Metabolic syndrome (N, %) | 16 (16) |
| Hepatic steatosis on US: none/mild/moderate or severe‡ (N, %) | 78/19/5 (76/19/5) |
S.D., standard deviation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; HBeAg, hepatitis B envelope antigen; APRI, AST to Platelet Ratio Index; FIB-4, fibrosis-4; HDL, high-density lipoprotein; LDL, low-density lipoprotein; US, ultrasonography.
*
Significant alcohol consumption is defined as drinking above 210 gram/week for men and above 140 gram/week for women.
†
The variables were measured by electrical impedance analysis.
‡
Hepatic steatosis was semiquantitatively evaluated using Hamaguchi’s scoring system on ultrasonography (0-6): 0-1, no steatosis; 2-3, mild steatosis; ≥4, moderate or severe steatosis